首页> 外文期刊>BMC Immunology >Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in rats
【24h】

Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in rats

机译:组蛋白甲基转移酶EzH2的抑制改善了大鼠早期急性肾同种异体移植物排斥反应

获取原文
           

摘要

Background Although histone methyltransferases EZH2 has been proved to have significant regulatory effect on the immune rejection after hematopoietic stem cell transplantation, its role in solid-organ transplantation remains uncovered. In this study, we investigate whether histone methylation regulation can impact renal allograft rejection in rat models. Results Allogeneic rat renal transplantation model (Wistar to Lewis) was established, and the recipients were administrated with EZH2 inhibitor DZNep after transplantation. Renal allografts and peripheral blood were collected on day 5 after transplantation for histological examination and mechanism investigation. We found that inhibition of EZH2 by DZNep after transplantation significantly ameliorated acute rejection (AR), with decreased histological injury and reduced inflammatory infiltration in renal allografts. Attenuation of AR was due to the prohibited activation of alloreactive T cells, the subsequent impaired production of inflammatory cytokines, and also the elevated apoptosis of alloreactive T cells in both renal allografts and periphery. However, inhibition of EZH2 did not increase the regulatory T cells during the AR. Conclusions Disruption of EZH2 by DZNep suppressed the immune responses of alloreactive T cells and ameliorated AR of renal allografts. This suggests a therapeutic potential of targeting histone methyltransferases EZH2 in treating allograft rejection after solid organ transplantation.
机译:背景技术虽然已被证明在造血干细胞移植后对组蛋白甲基转移酶EZH2对免疫排斥产生显着的调节作用,但其在固体器官移植中的作用仍未发现。在这项研究中,我们研究组蛋白甲基化调控是否会影响大鼠模型中肾同种异体移植物排斥反应。结果建立了同种异体大鼠肾移植模型(Wistar至Lewis),接受者在移植后通过EZH2抑制剂DZNEP给予。在移植组织学检查和机制调查后第5天收集肾同种异体移植物和外周血。我们发现在移植后DZNEP抑制EZH2显着改善急性排斥(AR),随着组织学损伤的降低和肾同种异体移植物的炎症性渗透降低。 AR的衰减是由于禁止的氨反应性T细胞的激活,随后的炎性细胞因子的产生,以及肾同种异体移植物和周边的聚糖T细胞的凋亡升高。然而,抑制EZH2在AR期间没有增加调节性T细胞。结论DZNEP的ezH2破坏抑制了肾同种异体移植物的含有成分性T细胞的免疫应答和改善ar。这表明在固体器官移植后靶向组蛋白甲基转移酶EzH2的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号